Infliximab is the first-line agent of choice for pustular psoriasis, dermatologists suggest, but ustekinumab is a good alternative. 

Researchers conducted a systematic review analysing data from about 40 articles, published between 2012 and 2018, on biologic therapies used to manage the rare but potentially life-threatening disease.

The dermatologists, from the University of Puerto Rico’s Medical Science Campus, said there was limited evidence on pustular psoriasis treatment strategies.

“Factors including its relatively infrequent presentation have contributed to a lack of sound scientific data regarding management,” they said.